Form 4: Cytek Biosciences Director Vera Imper Receives Significant Equity Award

Cytek Biosciences, Inc. Director Vera Imper was granted 43,973 Restricted Stock Units and options to purchase 23,809 shares of common stock, aligning her interests with shareholders.

Summary

• Vera Imper, a Director of Cytek Biosciences, Inc. (CTKB), was granted new equity awards on June 18, 2025.
• The awards include 43,973 Restricted Stock Units (RSUs), each representing a contingent right to receive one share of the Issuer's common stock.
• The RSU award vests 100% on the earlier of June 18, 2026, and the date of the Issuer's 2026 annual meeting of stockholders (provided such meeting is held in June 2026).
• Additionally, Ms. Imper received options to purchase 23,809 shares of common stock with an exercise price of $3.07 per share.
• The stock options also vest 100% on the earlier of June 18, 2026, and the date of the Issuer's 2026 annual meeting of stockholders (provided such meeting is held in June 2026), and expire on June 18, 2035.
• Following these transactions, Ms. Imper beneficially owns 43,973 Restricted Stock Units and 23,809 Director Stock Options directly.

Sentiment

Score: 7

Explanation: The document reports a standard equity compensation award to a director, which is a positive for aligning interests but not a significant market-moving event. It reflects normal corporate operations.

Positives

• The equity awards align the director's financial interests with those of the shareholders, incentivizing long-term performance and value creation.
• Granting of equity compensation is a standard practice for attracting and retaining qualified board members.

Negatives

• The future issuance of shares upon vesting of RSUs and exercise of options could lead to minor dilution for existing shareholders, though this is a common aspect of equity compensation plans.

Future Outlook

The equity awards are set to vest on the earlier of June 18, 2026, or the date of the Issuer's 2026 annual meeting of stockholders (provided such meeting is held in June 2026), indicating a future increase in the director's direct share ownership.

Industry Context

The granting of equity compensation, such as Restricted Stock Units and stock options, to directors is a common practice across various industries, including the life sciences sector where Cytek Biosciences operates. This method is widely used to align the interests of board members with long-term shareholder value.

Comparison to Industry Standards

• The structure of the equity award, including RSUs and stock options with a vesting schedule, is consistent with typical director compensation packages observed in publicly traded companies within the biotechnology and life sciences industries.
• While specific comparable companies or projects are not detailed in this Form 4, the general approach to director compensation aligns with global benchmarks for corporate governance and incentive alignment.

Corporate Governance

Related Party Transactions

• The equity awards granted to Director Vera Imper constitute a related party transaction, as it involves compensation provided by the company to a member of its board of directors.

Stakeholder Impact

• Shareholders: Positive impact due to increased alignment of director's interests with long-term shareholder value.
• Director (Vera Imper): Positive impact through increased equity stake and potential for future financial gain based on company performance.

Next Steps

• Vesting of 43,973 Restricted Stock Units on the earlier of June 18, 2026, or the 2026 annual meeting.
• Vesting of 23,809 Director Stock Options on the earlier of June 18, 2026, or the 2026 annual meeting.
• Potential exercise of Director Stock Options by June 18, 2035.

Key Dates

Keywords

Cytek Biosciences, CTKB, SEC Form 4, Insider Transaction, Director Compensation, Restricted Stock Units, Stock Options, Equity Award, Beneficial Ownership